Why Is ENVB Stock Rising Today?

• Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways.
• The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.
• Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.

Enveric Biosciences Inc. (SOPA) shares gained over 7% in Monday’s pre-market trade after the company announced that it has been issued a patent that covers novel molecules with likely applications for the treatment of neuropsychiatric conditions.

The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.

Retail sentiment on Stocktwits around Enveric Biosciences trended in the ‘bearish’ territory at the time of writing.

Licensing Opportunity

Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways. The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.

Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.

Patent Details

Enveric stated that the molecules covered by this patent are based on known compounds with relevant pharmacological activity. It added that these compounds are chemically altered to improve efficacy while reducing side effects compared to existing compounds.

“Enveric’s growing pipeline of patented molecules expands the available opportunities to develop next-generation treatments for neuropsychiatric conditions, leveraging our innovative research,” said Enveric CEO Joseph Tucker.

Enveric is a Massachusetts-based biotechnology company focused on developing small-molecule neuroplastogenic therapeutics for the treatment of psychiatric and neurological disorders.

ENVB stock is down 99.6% year-to-date and 99.5% over the past 12 months.

Also See: Paul Krugman Warns 2026 Will Be Worse For Small Businesses, A Month After Small Firms Cut 120,000 Jobs

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on